Literature DB >> 21885258

Comparing the PANSS in Chinese and American inpatients: cross-cultural psychiatric analyses of instrument translation and implementation.

Neil Krishan Aggarwal1, Haojuan Tao, Ke Xu, Elina Stefanovics, Liu Zhening, Robert A Rosenheck.   

Abstract

This article compares data from the Positive and Negative Syndrome Scale (PANSS) collected from Chinese and American inpatients diagnosed with schizophrenia to show how patterned differences in item ratings may reflect cultural attitudes of the raters. The Chinese sample (N=553) was based on consecutive admissions to four academic hospitals in Changsha, China. Only patients ill for 3 or more years were included in the analysis to match the chronically ill sample represented in the US CATIE sample. A total of 261 PANSS assessments were completed during a month when CATIE subjects had been hospitalized for 15 days or more to optimize equivalence of the US and Chinese samples. Controlling for age and gender, the total PANSS and the three sub-scores were all significantly lower in the Chinese than in the US CATIE sample by 5-8% (all p<.05). However, on 9 items, the Chinese sample scored 10-30% higher than the US sample (all p<.05) and on 5 items they scored over 20% higher (all p<.0001). These items rated increased hostility, poorer attention, lack of judgment and insight, disturbance of volition, and poorer impulse control. We ascribe these differences to cultural variations in the ways individuals relate to others in their social environment within Chinese and American societies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21885258     DOI: 10.1016/j.schres.2011.08.003

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?

Authors:  Ariana Anderson; Marsha Wilcox; Adam Savitz; Hearee Chung; Qingqin Li; Giacomo Salvadore; Dai Wang; Isaac Nuamah; Steven P Riese; Robert M Bilder
Journal:  Psychiatry Res       Date:  2015-01-06       Impact factor: 3.222

2.  Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia.

Authors:  Ke Xu; John H Krystal; Yuping Ning; Da Chun Chen; Hongbo He; Daping Wang; Xiaoyin Ke; Xifan Zhang; Yi Ding; Yuping Liu; Ralitza Gueorguieva; Zuoheng Wang; Diana Limoncelli; Robert H Pietrzak; Ismene L Petrakis; Xiangyang Zhang; Ni Fan
Journal:  J Psychiatr Res       Date:  2014-12-24       Impact factor: 4.791

Review 3.  Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.

Authors:  Jean-Pierre Lindenmayer
Journal:  Innov Clin Neurosci       Date:  2017-12-01

4.  Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China.

Authors:  Somaia Mohamed; Robert Rosenheck; Hongbo He; Ning Yuping
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

5.  Rater evaluations for psychiatric instruments and cultural differences: the positive and negative syndrome scale in China and the United States.

Authors:  Neil Krishan Aggarwal; Xiang Yang Zhang; Elina Stefanovics; Da Chun Chen; Mei Hong Xiu; Ke Xu; Robert A Rosenheck
Journal:  J Nerv Ment Dis       Date:  2012-09       Impact factor: 2.254

6.  A rasch model to test the cross-cultural validity in the positive and negative syndrome scale (PANSS) across six geo-cultural groups.

Authors:  Anzalee Khan; Christian Yavorsky; Stacy Liechti; Mark Opler; Brian Rothman; Guillermo DiClemente; Luka Lucic; Sofija Jovic; Toshiya Inada; Lawrence Yang
Journal:  BMC Psychol       Date:  2013-03-11

Review 7.  Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.

Authors:  Hai Bo Haber Xue; Li Liu; Hena Zhang; William Montgomery; Tamás Treuer
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-16       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.